vs

Side-by-side financial comparison of FS Bancorp, Inc. (FSBW) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

FS Bancorp, Inc. is the larger business by last-quarter revenue ($40.0M vs $35.5M, roughly 1.1× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 12.0%). FS Bancorp, Inc. produced more free cash flow last quarter ($51.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 6.2%).

FS Bancorp, Inc. is a U.S.-headquartered bank holding company that serves as the parent of 1st Security Bank of Washington. It offers a full range of personal and commercial banking solutions including deposit products, mortgage loans, small business financing and construction loans, primarily catering to customers in the Pacific Northwest, with core segments covering retail banking, commercial banking and residential lending.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FSBW vs RXRX — Head-to-Head

Bigger by revenue
FSBW
FSBW
1.1× larger
FSBW
$40.0M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+669.7% gap
RXRX
681.7%
12.0%
FSBW
More free cash flow
FSBW
FSBW
$99.3M more FCF
FSBW
$51.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
6.2%
FSBW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FSBW
FSBW
RXRX
RXRX
Revenue
$40.0M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
25.8%
-304.8%
Net Margin
-304.2%
Revenue YoY
12.0%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$1.11
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSBW
FSBW
RXRX
RXRX
Q4 25
$40.0M
$35.5M
Q3 25
$39.3M
$5.2M
Q2 25
$37.3M
$19.2M
Q1 25
$36.1M
$14.7M
Q4 24
$35.7M
$4.5M
Q3 24
$37.2M
$26.1M
Q2 24
$36.3M
$14.4M
Q1 24
$35.5M
$13.8M
Net Profit
FSBW
FSBW
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$9.2M
$-162.3M
Q2 25
$7.7M
$-171.9M
Q1 25
$8.0M
$-202.5M
Q4 24
$-178.9M
Q3 24
$10.3M
$-95.8M
Q2 24
$9.0M
$-97.5M
Q1 24
$8.4M
$-91.4M
Gross Margin
FSBW
FSBW
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FSBW
FSBW
RXRX
RXRX
Q4 25
25.8%
-304.8%
Q3 25
29.5%
-3327.6%
Q2 25
26.2%
-916.8%
Q1 25
26.2%
-1297.9%
Q4 24
27.6%
-4042.4%
Q3 24
26.5%
-377.1%
Q2 24
31.3%
-697.4%
Q1 24
29.7%
-698.4%
Net Margin
FSBW
FSBW
RXRX
RXRX
Q4 25
-304.2%
Q3 25
23.4%
-3135.3%
Q2 25
20.7%
-894.2%
Q1 25
22.2%
-1373.3%
Q4 24
-3935.5%
Q3 24
27.6%
-367.5%
Q2 24
24.7%
-676.6%
Q1 24
23.7%
-662.4%
EPS (diluted)
FSBW
FSBW
RXRX
RXRX
Q4 25
$1.11
$-0.17
Q3 25
$1.18
$-0.36
Q2 25
$0.99
$-0.41
Q1 25
$1.01
$-0.50
Q4 24
$0.88
$-0.56
Q3 24
$1.29
$-0.34
Q2 24
$1.13
$-0.40
Q1 24
$1.06
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSBW
FSBW
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$28.2M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$307.7M
$1.1B
Total Assets
$3.2B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSBW
FSBW
RXRX
RXRX
Q4 25
$28.2M
$743.3M
Q3 25
$61.3M
$659.8M
Q2 25
$33.2M
$525.1M
Q1 25
$62.7M
$500.5M
Q4 24
$31.6M
$594.4M
Q3 24
$40.3M
$427.6M
Q2 24
$33.0M
$474.3M
Q1 24
$45.4M
$296.3M
Total Debt
FSBW
FSBW
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FSBW
FSBW
RXRX
RXRX
Q4 25
$307.7M
$1.1B
Q3 25
$300.5M
$1.0B
Q2 25
$297.2M
$919.1M
Q1 25
$298.8M
$933.9M
Q4 24
$295.8M
$1.0B
Q3 24
$288.9M
$524.6M
Q2 24
$284.0M
$584.4M
Q1 24
$277.9M
$401.2M
Total Assets
FSBW
FSBW
RXRX
RXRX
Q4 25
$3.2B
$1.5B
Q3 25
$3.2B
$1.4B
Q2 25
$3.2B
$1.3B
Q1 25
$3.1B
$1.3B
Q4 24
$3.0B
$1.4B
Q3 24
$3.0B
$726.5M
Q2 24
$2.9B
$775.9M
Q1 24
$3.0B
$557.8M
Debt / Equity
FSBW
FSBW
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSBW
FSBW
RXRX
RXRX
Operating Cash FlowLast quarter
$72.3M
$-46.1M
Free Cash FlowOCF − Capex
$51.9M
$-47.3M
FCF MarginFCF / Revenue
129.8%
-133.1%
Capex IntensityCapex / Revenue
50.9%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$107.2M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSBW
FSBW
RXRX
RXRX
Q4 25
$72.3M
$-46.1M
Q3 25
$44.6M
$-117.4M
Q2 25
$7.1M
$-76.4M
Q1 25
$8.2M
$-132.0M
Q4 24
$50.8M
$-115.4M
Q3 24
$-891.0K
$-59.2M
Q2 24
$9.9M
$-82.2M
Q1 24
$275.0K
$-102.3M
Free Cash Flow
FSBW
FSBW
RXRX
RXRX
Q4 25
$51.9M
$-47.3M
Q3 25
$41.6M
$-117.6M
Q2 25
$5.9M
$-79.6M
Q1 25
$7.8M
$-133.8M
Q4 24
$49.2M
$-116.7M
Q3 24
$-1.5M
$-63.8M
Q2 24
$9.6M
$-83.4M
Q1 24
$-82.0K
$-109.0M
FCF Margin
FSBW
FSBW
RXRX
RXRX
Q4 25
129.8%
-133.1%
Q3 25
105.9%
-2272.5%
Q2 25
15.7%
-413.9%
Q1 25
21.7%
-907.4%
Q4 24
137.7%
-2567.7%
Q3 24
-4.1%
-244.6%
Q2 24
26.6%
-578.5%
Q1 24
-0.2%
-789.9%
Capex Intensity
FSBW
FSBW
RXRX
RXRX
Q4 25
50.9%
3.5%
Q3 25
7.7%
4.7%
Q2 25
3.5%
16.4%
Q1 25
1.0%
12.4%
Q4 24
4.6%
28.6%
Q3 24
1.7%
17.5%
Q2 24
0.8%
8.2%
Q1 24
1.0%
48.2%
Cash Conversion
FSBW
FSBW
RXRX
RXRX
Q4 25
Q3 25
4.86×
Q2 25
0.92×
Q1 25
1.02×
Q4 24
Q3 24
-0.09×
Q2 24
1.11×
Q1 24
0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons